Error message

No crossref credentials set for genesdev

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis

Genes & Dev., 15 July 2007
Vol. 21, Issue 14, p. 1714-1719
DOI: 10.1101/gad.1549407

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis

  1. Brooke Ancrile,
  2. Kian-Huat Lim, and
  3. Christopher M. Counter1
  1. Department of Pharmacology and Cancer Biology, Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA

Abstract

Ras is mutated to remain in the active oncogenic state in many cancers. As Ras has proven difficult to target therapeutically, we searched for secreted, druggable proteins induced by Ras that are required for tumorigenesis. We found that Ras induces the secretion of cytokine IL6 in different cell types, and that knockdown of IL6, genetic ablation of the IL6 gene, or treatment with a neutralizing IL6 antibody retard Ras-driven tumorigenesis. IL6 appears to act in a paracrine fashion to promote angiogenesis and tumor growth. Inhibiting IL6 may therefore have therapeutic utility for treatment of cancers characterized by oncogenic Ras mutations.

  • Ras
  • oncogene
  • IL6
  • cytokine
  • cancer

Footnotes

Citation:

B. Ancrile, K.-H. Lim, and C. M. Counter, Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes & Dev. 21, 1714-1719 (2007).

Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer
C. Shi, Y. Yang, Y. Xia, Y. Okugawa, J. Yang, Y. Liang, H. Chen, P. Zhang, F. Wang, H. Han et al.
Gut 0, gutjnl-2014-308455v1-gutjnl-2014-308455 (20 May 2015)

Curcumin and Cancer Stem Cells: Curcumin Has Asymmetrical Effects on Cancer and Normal Stem Cells
P. P. SORDILLO, and L. HELSON
Anticancer Res 35, 599-614 (1 February 2015)

PAD2 Overexpression in Transgenic Mice Promotes Spontaneous Skin Neoplasia
J. L. McElwee, S. Mohanan, S. Horibata, K. L. Sams, L. J. Anguish, D. McLean, I. Cvitaš, J. J. Wakshlag, and S. A. Coonrod
Cancer Res. 74, 6306-6317 (1 November 2014)

Caught in the cross fire: p53 in inflammation
T. Cooks, C. C. Harris, and M. Oren
Carcinogenesis 35, 1680-1690 (1 August 2014)

STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia
J. Munoz, N. Dhillon, F. Janku, S. S. Watowich, and D. S. Hong
The Oncologist 19, 536-544 (1 May 2014)

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
E. Angevin, J. Tabernero, E. Elez, S. J. Cohen, R. Bahleda, J.-L. van Laethem, C. Ottensmeier, J. A. Lopez-Martin, S. Clive, F. Joly et al.
Clin. Cancer Res. 20, 2192-2204 (15 April 2014)

Autophagy-Dependent Production of Secreted Factors Facilitates Oncogenic RAS-Driven Invasion
R. Lock, C. M. Kenific, A. M. Leidal, E. Salas, and J. Debnath
Cancer Discovery 4, 466-479 (1 April 2014)

Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Z. Zhu, A. R. Aref, T. J. Cohoon, T. U. Barbie, Y. Imamura, S. Yang, S. E. Moody, R. R. Shen, A. C. Schinzel, T. C. Thai et al.
Cancer Discovery 4, 452-465 (1 April 2014)

Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRasG12V-driven pancreatic tumourigenesis
M. Flandez, J. Cendrowski, M. Canamero, A. Salas, N. del Pozo, K. Schoonjans, and F. X. Real
Gut 63, 647-655 (1 April 2014)

Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation, and Cell Cycle: Role and Targeting
F. M. S. Gurgis, W. Ziaziaris, and L. Munoz
Mol. Pharmacol. 85, 345-356 (1 February 2014)

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
A. B. Nixon, H. Pang, M. D. Starr, P. N. Friedman, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, H. I. Hurwitz, for the Alliance for Clinical Trials In Oncology et al.
Clin. Cancer Res. 19, 6957-6966 (15 December 2013)

Interleukin-6 Is Required for Pancreatic Cancer Progression by Promoting MAPK Signaling Activation and Oxidative Stress Resistance
Y. Zhang, W. Yan, M. A. Collins, F. Bednar, S. Rakshit, B. R. Zetter, B. Z. Stanger, I. Chung, A. D. Rhim, M. P. di Magliano et al.
Cancer Res. 73, 6359-6374 (15 October 2013)

Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
Z. C. Hartman, G. M. Poage, P. den Hollander, A. Tsimelzon, J. Hill, N. Panupinthu, Y. Zhang, A. Mazumdar, S. G. Hilsenbeck, G. B. Mills et al.
Cancer Res. 73, 3470-3480 (1 June 2013)

Loss of the Transcription Factor GLI1 Identifies a Signaling Network in the Tumor Microenvironment Mediating KRAS Oncogene-induced Transformation
L. D. Mills, Y. Zhang, R. J. Marler, M. Herreros-Villanueva, L. Zhang, L. L. Almada, F. Couch, C. Wetmore, M. Pasca di Magliano, M. E. Fernandez-Zapico et al.
J Biol Chem 288, 11786-11794 (26 April 2013)

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
J. S. Khalili, S. Liu, T. G. Rodriguez-Cruz, M. Whittington, S. Wardell, C. Liu, M. Zhang, Z. A. Cooper, D. T. Frederick, Y. Li et al.
Clin. Cancer Res. 18, 5329-5340 (1 October 2012)

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
C. Smith, M. Y. Chang, K. H. Parker, D. W. Beury, J. B. DuHadaway, H. E. Flick, J. Boulden, E. Sutanto-Ward, A. P. Soler, L. D. Laury-Kleintop et al.
Cancer Discovery 2, 722-735 (1 August 2012)

Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling
X. Jin, S.-H. Kim, H.-M. Jeon, S. Beck, Y.-W. Sohn, J. Yin, J.-K. Kim, Y. C. Lim, J.-H. Lee, S.-H. Kim et al.
Brain 135, 1055-1069 (1 April 2012)

Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
P. Sansone, and J. Bromberg
JCO 30, 1005-1014 (20 March 2012)

Multifaceted link between cancer and inflammation
G. Sethi, M. K. Shanmugam, L. Ramachandran, A. P. Kumar, and V. Tergaonkar
Biosci. Rep. 32, 1-15 (1 February 2012)

Inhibition of the Notch-Hey1 Axis Blocks Embryonal Rhabdomyosarcoma Tumorigenesis
B. C. Belyea, S. Naini, R. C. Bentley, and C. M. Linardic
Clin. Cancer Res. 17, 7324-7336 (1 December 2011)

Identification of Tumorigenic Cells in KrasG12D-Induced Lung Adenocarcinoma
H.-C. Cho, C.-Y. Lai, L.-E. Shao, and J. Yu
Cancer Res. 71, 7250-7258 (1 December 2011)

EGFR-AKT-Smad Signaling Promotes Formation of Glioma Stem-like Cells and Tumor Angiogenesis by ID3-Driven Cytokine Induction
X. Jin, J. Yin, S.-H. Kim, Y.-W. Sohn, S. Beck, Y. C. Lim, D.-H. Nam, Y.-J. Choi, and H. Kim
Cancer Res. 71, 7125-7134 (15 November 2011)

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
J. Coward, H. Kulbe, P. Chakravarty, D. Leader, V. Vassileva, D. A. Leinster, R. Thompson, T. Schioppa, J. Nemeth, J. Vermeulen et al.
Clin. Cancer Res. 17, 6083-6096 (15 September 2011)

CXCR3 Enhances a T-Cell-Dependent Epidermal Proliferative Response and Promotes Skin Tumorigenesis
A. E. Winkler, J. J. Brotman, M. E. Pittman, N. P. Judd, J. S. Lewis, R. D. Schreiber, and R. Uppaluri
Cancer Res. 71, 5707-5716 (1 September 2011)

IL-8 Signaling Plays a Critical Role in the Epithelial-Mesenchymal Transition of Human Carcinoma Cells
R. I. Fernando, M. D. Castillo, M. Litzinger, D. H. Hamilton, and C. Palena
Cancer Res. 71, 5296-5306 (1 August 2011)

HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for Tumorigenesis
Z. C. Hartman, X.-Y. Yang, O. Glass, G. Lei, T. Osada, S. S. Dave, M. A. Morse, T. M. Clay, and H. K. Lyerly
Cancer Res. 71, 4380-4391 (1 July 2011)

Hyperproliferation, cancer, and inflammation in mice expressing a {Delta}133p53-like isoform
T. L. Slatter, N. Hung, H. Campbell, C. Rubio, R. Mehta, P. Renshaw, G. Williams, M. Wilson, A. Engelmann, A. Jeffs et al.
Blood 117, 5166-5177 (12 May 2011)

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
M. S. Anglesio, J. George, H. Kulbe, M. Friedlander, D. Rischin, C. Lemech, J. Power, J. Coward, P. A. Cowin, C. M. House et al.
Clin. Cancer Res. 17, 2538-2548 (15 April 2011)

Four faces of cellular senescence
F. Rodier, and J. Campisi
JCB 192, 547-556 (21 February 2011)

Interleukin 6, but Not T Helper 2 Cytokines, Promotes Lung Carcinogenesis
C. E. Ochoa, S. G. Mirabolfathinejad, V. A. Ruiz, S. E. Evans, M. Gagea, C. M. Evans, B. F. Dickey, and S. J. Moghaddam
Cancer Prev Res 4, 51-64 (1 January 2011)

K-ras Mutation Targeted to Gastric Tissue Progenitor Cells Results in Chronic Inflammation, an Altered Microenvironment, and Progression to Intraepithelial Neoplasia
T. Okumura, R. E. Ericksen, S. Takaishi, S. S. W. Wang, Z. Dubeykovskiy, W. Shibata, K. S. Betz, S. Muthupalani, A. B. Rogers, J. G. Fox et al.
Cancer Res. 70, 8435-8445 (1 November 2010)

TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells
D. Mittal, F. Saccheri, E. Venereau, T. Pusterla, M. E. Bianchi, and M. Rescigno
EMBO J. 29, 2242-2252 (7 July 2010)

An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett's oesophagus, which regulates NF-{kappa}B activation and cytokine levels
S. P. Duggan, F. M. Behan, M. Kirca, S. Smith, J. V. Reynolds, A. Long, and D. Kelleher
Carcinogenesis 31, 936-945 (1 May 2010)

STAT2 Contributes to Promotion of Colorectal and Skin Carcinogenesis
A. M. Gamero, M. R. Young, R. Mentor-Marcel, G. Bobe, A. J. Scarzello, J. Wise, and N. H. Colburn
Cancer Prev Res 3, 495-504 (1 April 2010)

p53 Regulates the Ras Circuit to Inhibit the Expression of a Cancer-Related Gene Signature by Various Molecular Pathways
Y. Buganim, H. Solomon, Y. Rais, D. Kistner, I. Nachmany, M. Brait, S. Madar, I. Goldstein, E. Kalo, N. Adam et al.
Cancer Res. 70, 2274-2284 (15 March 2010)

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
J. R. Dry, S. Pavey, C. A. Pratilas, C. Harbron, S. Runswick, D. Hodgson, C. Chresta, R. McCormack, N. Byrne, M. Cockerill et al.
Cancer Res. 70, 2264-2273 (15 March 2010)

Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
A. J. Schetter, N. H. H. Heegaard, and C. C. Harris
Carcinogenesis 31, 37-49 (1 January 2010)

Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia
A. Tsaalbi-Shtylik, J. W. A. Verspuy, J. G. Jansen, H. Rebel, L. M. Carlee, M. A. van der Valk, J. Jonkers, F. R. de Gruijl, and N. de Wind
Proc. Natl. Acad. Sci. USA 106, 21836-21841 (22 December 2009)

ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis
K. M. O'Hayer, D. C. Brady, and C. M. Counter
Carcinogenesis 30, 1841-1847 (1 November 2009)

Hyperactivated NF-{kappa}B and AP-1 Transcription Factors Promote Highly Accessible Chromatin and Constitutive Transcription across the Interleukin-6 Gene Promoter in Metastatic Breast Cancer Cells
M. N. Ndlovu, C. Van Lint, K. Van Wesemael, P. Callebert, D. Chalbos, G. Haegeman, and W. Vanden Berghe
Mol. Cell. Biol. 29, 5488-5504 (15 October 2009)

Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma
S. Shinriki, H. Jono, K. Ota, M. Ueda, M. Kudo, T. Ota, Y. Oike, M. Endo, M. Ibusuki, A. Hiraki et al.
Clin. Cancer Res. 15, 5426-5434 (1 September 2009)

ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis
T. Iriyama, K. Takeda, H. Nakamura, Y. Morimoto, T. Kuroiwa, J. Mizukami, T. Umeda, T. Noguchi, I. Naguro, H. Nishitoh et al.
EMBO J. 28, 843-853 (8 April 2009)

A Role for CXCR2 in Senescence, but What about in Cancer?
J. C. Acosta, and J. Gil
Cancer Res. 69, 2167-2170 (15 March 2009)

Depletion of Cytosolic Phospholipase A2 in Bone Marrow-Derived Macrophages Protects against Lung Cancer Progression and Metastasis
M. C.M. Weiser-Evans, X.-Q. Wang, J. Amin, V. Van Putten, R. Choudhary, R. A. Winn, R. Scheinman, P. Simpson, M. W. Geraci, R. A. Nemenoff et al.
Cancer Res. 69, 1733-1738 (1 March 2009)

Protein Kinase C{zeta} Represses the Interleukin-6 Promoter and Impairs Tumorigenesis In Vivo
A. S. Galvez, A. Duran, J. F. Linares, P. Pathrose, E. A. Castilla, S. Abu-Baker, M. Leitges, M. T. Diaz-Meco, and J. Moscat
Mol. Cell. Biol. 29, 104-115 (1 January 2009)

Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6-Dependent Manner
A. W. Studebaker, G. Storci, J. L. Werbeck, P. Sansone, A. K. Sasser, S. Tavolari, T. Huang, M. W.Y. Chan, F. C. Marini, T. J. Rosol et al.
Cancer Res. 68, 9087-9095 (1 November 2008)

The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
Y.-S. Lee, K.-H. Lim, X. Guo, Y. Kawaguchi, Y. Gao, T. Barrientos, P. Ordentlich, X.-F. Wang, C. M. Counter, T.-P. Yao et al.
Cancer Res. 68, 7561-7569 (15 September 2008)

Reduced Colitis-Associated Colon Cancer in Fat-1 (n-3 Fatty Acid Desaturase) Transgenic Mice
Q. Jia, J. R. Lupton, R. Smith, B. R. Weeks, E. Callaway, L. A. Davidson, W. Kim, Y.-Y. Fan, P. Yang, R. A. Newman et al.
Cancer Res. 68, 3985-3991 (15 May 2008)

Targeting oncogenic Ras
E. Diaz-Flores, and K. Shannon
Genes Dev. 21, 1989-1992 (15 August 2007)

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882